Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
trial safety
Biotech
Ultragenyx granted go-ahead to up doses for Angelman therapy
Ultragenyx and partner GeneTx have been given the go-ahead to up the dose in a phase 1/2 Angelman syndrome trial of antisense treatment GTX-102.
Annalee Armstrong
Jan 5, 2022 11:11am
Takeda stops narcolepsy clinical trials because of safety signal
Oct 6, 2021 4:45am
Acorda dumps $363M Parkinson’s drug after patient deaths
Nov 20, 2017 8:34am
Theravance COPD drug clears safety study, setting up NDA
Jul 20, 2017 6:44am
Juno ditches lead CAR-T program following patient deaths
Mar 2, 2017 4:03am
EMA updates first-in-human trial guidance
Nov 16, 2016 12:10pm
